Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t

Item

http://www.wikidata.org/entity/Q34321875

Q34321875

about

Definition of a molecular pathway mediating α-synuclein neurotoxicity Evaluation of Models of Parkinson's Disease Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.α-Synuclein and nonhuman primate models of Parkinson's disease Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo.Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases.Direct detection of alpha synuclein oligomers in vivo AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.Pathways towards an effective immunotherapy for Parkinson's disease Inflammation and adaptive immunity in Parkinson's disease.Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.α-Synuclein nonhuman primate models of Parkinson's disease.Animal models of α-synucleinopathy for Parkinson disease drug development.Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease.Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.In vivo models of alpha-synuclein transmission and propagation.Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome.MicroRNAs in Parkinson's disease and emerging therapeutic targets.A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

P2860

Q26269832-8E0840C3-FA9C-484B-BFC9-83ADA43242E5 Q26772843-C920C6F2-C4B2-4041-A557-E3C154E4DFCE Q27318127-471A6C4F-8A48-4F56-9258-F8C62962868D Q28538890-96AF4176-2906-477D-B44C-9697B12C3FFD Q28554611-EF13C090-0A39-4498-B512-95B917574CCD Q30373366-3FDC230B-8510-4173-A165-B14F1073A495 Q33847712-FEEA01A4-19DD-4729-AFDD-5FF3CB769035 Q34465572-2C20E34A-5E71-4987-A228-FA4FBE22CBFD Q35853990-FBB1B852-C617-47DC-98D5-45B16967A56E Q36101699-92B3C307-C486-45A7-A226-66328849EC81 Q36157306-506B0C41-C10E-47A2-9BB3-7B9D44F12A6E Q36289970-87B0A0E4-A311-4815-A6BB-D055CD305793 Q36460964-9BC99ADA-2797-41DB-A1AE-DDD9FB6A5F84 Q37180232-9B8E38AB-6B12-4741-A2A1-1889CDCC2857 Q37618665-1D9349C3-1E43-4D7B-9923-1B35DB853C9B Q37957125-B9D29D1B-307B-4541-861D-FD1CF7B39FC5 Q37982378-4E0AF8BC-BE3E-4623-B879-F78F6AB595A0 Q38607819-F584EF28-EED4-441D-9175-628899F46E27 Q38790881-8D784736-91F3-40F6-9856-5F653B5213D3 Q38805550-D405445A-C901-4A8A-AD93-DEC0BE6DAE8E Q39256792-48BF6F3E-0779-4197-BDC5-3248E61C8858 Q40106906-D4F16AFC-DBC1-4C43-AEA6-CBAD20071A99 Q40922267-DBDA5E61-90A7-45B3-912D-38AEA8DAC87A Q41740088-C25F5568-669D-4ED3-BD28-20C42A6D644B Q46252300-A997E7B7-15CE-4446-8734-AAD957DEEDEC Q47111833-6A679020-4602-4D50-A9B2-98E107813C84 Q47304900-697B109B-3233-46F4-A0B3-A61726BF38B0 Q47870847-0CBAD826-7987-42CD-AFCA-ECA244F19C7F Q53684476-3D115732-5CE2-4BB0-B8B0-207DEFFB2B78 Q54486835-3E13BDB0-C44A-42C8-96FF-15463F15EA20

P2860

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t

Item

http://www.wikidata.org/entity/Q34321875

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue